Revisiting Aldosterone Synthase Inhibitors for Cardiovascular and Renal Management
Overview
Aldosterone synthase inhibitors (ASIs) represent a promising therapeutic alternative to mineralocorticoid receptor antagonists (MRAs) for managing cardiovascular and renal diseases characterized by aldosterone excess. Early phase II trials show ASIs effectively reduce blood pressure and urinary albumin excretion without affecting cortisol synthesis, addressing limitations of current MRAs.
Background
Aldosterone excess contributes to cardiovascular, endocrine, and renal pathologies by promoting inflammation, hypertrophy, and fibrosis beyond its classical renal effects. MRAs like spironolactone and eplerenone block aldosterone's harmful effects but have limitations including sexual side effects and hyperkalemia risk. New nonsteroidal MRAs have improved selectivity but remain limited in availability or efficacy. Aldosterone exerts both genomic and nongenomic effects, with the latter not fully inhibited by MRAs, prompting interest in targeting aldosterone synthesis directly via ASIs.
Data Highlights
Early phase II clinical trials demonstrated that selective ASIs reduce blood pressure in patients with uncontrolled hypertension and decrease urinary albumin excretion in proteinuric chronic kidney disease. These effects were achieved without impacting cortisol synthesis, indicating high selectivity for CYP11B2 inhibition. Ongoing longer-term studies aim to evaluate their impact on kidney disease progression and cardiovascular outcomes, including in combination with SGLT2 inhibitors.
Key Findings
Spironolactone, a steroidal MRA, effectively lowers blood pressure in resistant hypertension but is limited by sexual adverse effects and hyperkalemia risk.
Eplerenone offers greater receptor specificity but with less potency and limited global availability.
New nonsteroidal MRAs like finerenone reduce cardiovascular and renal outcomes but have modest blood pressure effects and risk of hyperkalemia.
MRAs induce compensatory increases in aldosterone, potentially overcoming receptor blockade and allowing MR-independent aldosterone effects.
Early clinical data show ASIs lower blood pressure and urinary albumin excretion, supporting their potential in cardiovascular and renal disease management.
Clinical Implications
ASIs may offer a novel approach to managing aldosterone-mediated cardiovascular and renal diseases by directly reducing aldosterone synthesis, potentially overcoming limitations of MRAs such as side effects and incomplete blockade of aldosterone actions. Their use could improve blood pressure control and reduce proteinuria, with ongoing studies needed to confirm long-term benefits and safety profiles.
Conclusion
Selective aldosterone synthase inhibitors represent a promising therapeutic advancement for cardiovascular and renal conditions driven by aldosterone excess, with early evidence supporting efficacy and improved tolerability compared to existing MRAs. Further clinical trials will clarify their role in routine clinical practice.
References
Revisiting Aldosterone Synthase Inhibitors for the Management of Cardiovascular and Renal Conditions, 2024
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
Patients are mining Reddit and TikTok for symptom intel while you're not — and a small study calls it epistemic injustice. Different knowledge, mutually unrecognized. Maybe ask where they've been reading before you wave it off as anecdote.
